Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 115Carboplatin 103Pemetrexed 90Cisplatin 58Paclitaxel 47osimertinib 41Drug Therapy 40Nivolumab 39Docetaxel 35Specimen Handling 33Magnetic Resonance Spectroscopy 28Bevacizumab 26durvalumab 23Gemcitabine 22cemiplimab 21Radiotherapy 20130-nm albumin-bound paclitaxel 20Radiosurgery 19tislelizumab 18atezolizumab 17aflutinib 15Cetuximab 15Immunotherapy 14Immune Checkpoint Inhibitors 14Platinum Compounds 13Ipilimumab 13Biopsy 12Standard of Care 11Surgical Procedures, Operative 10Injections 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Carcinoma, Non-Small-Cell Lung × MRX-2843 × Clear all
NCT04762199 2026-03-31

MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer

Emory University

Phase 1 Recruiting
69 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡